Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Palliat Care ; 36(2): 71-72, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33719781

ABSTRACT

Palliative care is uniquely positioned to optimize the care of the oncology patient through exploring unmet needs and utilizing interdisciplinary care. The studies presented here highlight some of the ways this can be done which includes: identifying patients at risk or in need; providing solutions to those requiring community supports; addressing psychological and existential concerns; managing symptoms over the course of a disease; communicating prognosis effectively and with compassion; exploring goals of care and advance directives; and facilitating conversations regarding goals, preferences, and values.


Subject(s)
Hospice and Palliative Care Nursing , Neoplasms , Palliative Care , Advance Directives , Humans , Medical Oncology
2.
Curr Heart Fail Rep ; 17(5): 314-323, 2020 10.
Article in English | MEDLINE | ID: mdl-32830304

ABSTRACT

PURPOSE OF REVIEW: Heart failure (HF) is a significant cause of morbidity, mortality, and decreased quality of life (QOL). Symptoms, including reduced activity tolerance, fatigue, palpitations, and dyspnea, result from volume overload or low output states. Herein, we review the best available literature supporting diuretic and inotropic therapies in advanced HF and how these improve QOL. RECENT FINDINGS: While diuretics and inotropes reduce symptoms and hospitalizations in advanced HF, there is an increased risk of harms with both modalities. While diuretic complications include electrolyte and renal function abnormalities, adverse event data with inotropes is more complex and includes possible arrhythmias and death. Further, inotrope utilization is complicated by required intravenous access, infusion costs, and limited outpatient support. Ambulatory use of diuretics and inotropes may improve patients' QOL through symptom management and reduced hospitalizations. However, risks and limitations of both modalities must be considered as treatment decisions are made.


Subject(s)
Ambulatory Care/methods , Cardiotonic Agents/therapeutic use , Diuretics/therapeutic use , Heart Failure/drug therapy , Palliative Care/methods , Heart Failure/physiopathology , Humans
4.
Am Fam Physician ; 85(10): 981-6, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22612050

ABSTRACT

Infectious endocarditis results from bacterial or fungal infection of the endocardial surface of the heart and is associated with significant morbidity and mortality. Risk factors include the presence of a prosthetic heart valve, structural or congenital heart disease, intravenous drug use, and a recent history of invasive procedures. Endocarditis should be suspected in patients with unexplained fevers, night sweats, or signs of systemic illness. Diagnosis is made using the Duke criteria, which include clinical, laboratory, and echocardiographic findings. Antibiotic treatment of infectious endocarditis depends on whether the involved valve is native or prosthetic, as well as the causative microorganism and its antibiotic susceptibilities. Common blood culture isolates include Staphylococcus aureus, viridans Streptococcus, enterococci, and coagulase-negative staphylococci. Valvular structural and functional integrity may be adversely affected in infectious endocarditis, and surgical consultation is warranted in patients with aggressive or persistent infections, emboli, and valvular compromise or rupture. After completion of antibiotic therapy, patients should be educated about the importance of daily dental hygiene, regular visits to the dentist, and the need for antibiotic prophylaxis before certain procedures.


Subject(s)
Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Family Practice/methods , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Streptococcal Infections/diagnosis , Streptococcal Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Endocarditis, Bacterial/prevention & control , Health Status , Heart Valve Prosthesis/microbiology , Humans , Primary Health Care/methods , Risk Factors , Staphylococcal Infections/prevention & control , Streptococcal Infections/prevention & control , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...